Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
fibrosis10255 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A08329 | 32151020 | Nutrients | Adipokines and Endotoxemia Correlate with Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease (NAFLD). | 2020 | Details |
| A08334 | 32149781 | Am J Gastroenterol | Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A08336 | 32149275 | JHEP Rep | Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism. | 2019 | Details |
| A08342 | 32147362 | J Hepatol | Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. | 2020 | Details |
| A08343 | 32147361 | J Hepatol | Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. | 2020 | Details |
| A08358 | 32145072 | Hepatology | Transcriptional Dynamics of Hepatic Sinusoid-Associated Cells After Liver Injury. | 2020 | Details |
| A08367 | 32141917 | Am J Gastroenterol | Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk. | 2020 | Details |
| A08370 | 32140062 | Int J Biol Sci | Aldehyde Dehydrogenase, Liver Disease and Cancer. | 2020 | Details |
| A08371 | 32139740 | Sci Rep | Odontogenic infection by Porphyromonas gingivalis exacerbates fibrosis in NASH via hepatic stellate cell activation. | 2020 | Details |
| A08373 | 32139507 | J Biol Chem | The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease. | 2020 | Details |
| A08374 | 32138869 | Ann Hepatol | Antiretroviral Therapies for Human Immunodeficiency Virus and Liver Disease: Challenges and opportunities. | 2021 | Details |
| A08377 | 32135582 | Gut Liver | Sarcopenia Is Independently Associated with the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus. | 2020 | Details |
| A08379 | 32135178 | J Hepatol | Inhibition of PU.1 ameliorates metabolic dysfunction and non-alcoholic steatohepatitis. | 2020 | Details |
| A08381 | 32133676 | Aliment Pharmacol Ther | Modelling NAFLD disease burden in four Asian regions-2019-2030. | 2020 | Details |
| A08384 | 32131439 | Cells | Hepatocyte Injury and Hepatic Stem Cell Niche in the Progression of Non-Alcoholic Steatohepatitis. | 2020 | Details |
| A08392 | 32128904 | J Intern Med | Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011-2016. | 2020 | Details |
| A08397 | 32126212 | Toxicol Appl Pharmacol | Benzyl isothiocyanate ameliorates high-fat/cholesterol/cholic acid diet-induced nonalcoholic steatohepatitis through inhibiting cholesterol crystal-activated NLRP3 inflammasome in Kupffer cells. | 2020 | Details |
| A08400 | 32124690 | Curr Pharm Des | Epidemiology of Non-alcoholic Fatty Liver Disease in North America. | 2020 | Details |
| A08402 | 32124651 | Expert Rev Gastroenterol Hepatol | The effects of epigenetic modification on the occurrence and progression of liver diseases and the involved mechanism. | 2020 | Details |
| A08404 | 32124221 | Obes Surg | Are Noninvasive Methods Comparable to Liver Biopsy in Postoperative Patients After Roux-en-Y Gastric Bypass? | 2020 | Details |
| A08406 | 32124215 | Obes Surg | Effects of Laparoscopic Sleeve Gastrectomy on Non-Alcoholic Steatohepatitis and Liver Fibrosis in Japanese Patients with Severe Obesity. | 2020 | Details |
| A08407 | 32124212 | Obes Surg | Evaluation of Liver Function Tests and Risk Score Assessment to Screen Patients for Significant Liver Disease Prior to Bariatric and Metabolic Surgery. | 2020 | Details |
| A08408 | 32124081 | J Gastroenterol | Fatty acid-driven modifications in T-cell profiles in non-alcoholic fatty liver disease patients. | 2020 | Details |
| A08413 | 32121602 | Nutrients | Citrus Peel Extract Ameliorates High-Fat Diet-Induced NAFLD via Activation of AMPK Signaling. | 2020 | Details |
| A08417 | 32119738 | J Nutr | One-Carbon Metabolism in Fatty Liver Disease and Fibrosis: One-Carbon to Rule Them All. | 2020 | Details |
| A08420 | 32118201 | JHEP Rep | Limitations of non-invasive tests for assessment of liver fibrosis. | 2020 | Details |
| A08427 | 32115759 | Hepatology | Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. | 2020 | Details |
| A08428 | 32115688 | Int J Cancer | Defects in long-chain 3-hydroxy acyl-CoA dehydrogenase lead to hepatocellular carcinoma: A novel etiology of hepatocellular carcinoma. | 2020 | Details |
| A08435 | 32111021 | Diagnostics (Basel) | Coronary Artery Disease is More Severe in Patients with Non-Alcoholic Steatohepatitis than Fatty Liver. | 2020 | Details |
| A08437 | 34035711 | Gastroenterol Hepatol (N Y) | Lifestyle Interventions Beyond Diet and Exercise for Patients With Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A08447 | 32106257 | PLoS One | Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease. | 2020 | Details |
| A08459 | 32103741 | BMC Gastroenterol | Fructo-oligosaccharides ameliorate steatohepatitis, visceral adiposity, and associated chronic inflammation via increased production of short-chain fatty acids in a mouse model of non-alcoholic steatohepatitis. | 2020 | Details |
| A08462 | 32102237 | Int J Mol Sci | Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. | 2020 | Details |
| A08471 | 32097065 | Br J Hosp Med (Lond) | Detecting chronic liver disease: are liver function tests the solution? | 2020 | Details |
| A08474 | 32096565 | Hepatology | Cardiolipin Synthase 1 Ameliorates NASH Through Activating Transcription Factor 3 Transcriptional Inactivation. | 2020 | Details |
| A08482 | 32092735 | Biomed Res | Placental extract ameliorates liver fibrosis in a methionine- and choline-deficient diet-induced mouse model of non-alcoholic steatohepatitis. | 2020 | Details |
| A08488 | 32090397 | Hepatol Res | Accuracy of the Enhanced Liver Fibrosis test, and combination of the Enhanced Liver Fibrosis and non-invasive tests for the diagnosis of advanced liver fibrosis in patients with non-alcoholic fatty liver disease. | 2020 | Details |
| A08490 | 32089754 | Dis Markers | Serum Golgi Protein 73 as a Potential Biomarker for Hepatic Necroinflammation in Population with Nonalcoholic Steatohepatitis. | 2020 | Details |
| A08493 | 32087038 | Liver Int | The amount of liver fat predicts mortality and development of type 2 diabetes in non-alcoholic fatty liver disease. | 2020 | Details |
| A08498 | 32086244 | J Lipid Res | Vitamin E does not prevent Western diet-induced NASH progression and increases metabolic flux dysregulation in mice. | 2020 | Details |
| A08509 | 32081971 | Sci Rep | CCN1 promotes hepatic steatosis and inflammation in non-alcoholic steatohepatitis. | 2020 | Details |
| A08514 | 32077617 | Liver Int | Non-invasive tests for liver fibrosis in NAFLD: Creating pathways between primary healthcare and liver clinics. | 2020 | Details |
| A08516 | 32077613 | Liver Int | A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions. | 2020 | Details |
| A08517 | 32077612 | Liver Int | Approach to the patient with chronic hepatitis B and decompensated cirrhosis. | 2020 | Details |
| A08518 | 32077609 | Liver Int | Current management of non-alcoholic steatohepatitis. | 2020 | Details |
| A08519 | 32077608 | Liver Int | Natural history of NASH and HCC. | 2020 | Details |
| A08522 | 32075905 | J Biol Chem | Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet-fed mice. | 2020 | Details |
| A08523 | 32075238 | Nutrients | Impact of the Co-Administration of N-3 Fatty Acids and Olive Oil Components in Preclinical Nonalcoholic Fatty Liver Disease Models: A Mechanistic View. | 2020 | Details |
| A08524 | 32075112 | Int J Mol Sci | Secondhand Smoke Induces Liver Steatosis through Deregulation of Genes Involved in Hepatic Lipid Metabolism. | 2020 | Details |
| A08529 | 32071558 | Int J Biol Sci | Mesenchymal stromal cells promote liver regeneration through regulation of immune cells. | 2020 | Details |
| A08535 | 32069503 | Semin Liver Dis | Drinking and Obesity: Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Interactions. | 2020 | Details |
| A08539 | 32068025 | Gastroenterology | Toward Genetic Prediction of Nonalcoholic Fatty Liver Disease Trajectories: PNPLA3 and Beyond. | 2020 | Details |
| A08540 | 32068022 | Gastroenterology | Metabolic Inflammation-A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease? | 2020 | Details |
| A08544 | 32066758 | Sci Rep | A Microbial Signature Identifies Advanced Fibrosis in Patients with Chronic Liver Disease Mainly Due to NAFLD. | 2020 | Details |
| A08545 | 32066623 | Gut | Advances in non-invasive assessment of hepatic fibrosis. | 2020 | Details |
| A08548 | 32065376 | Adv Ther | Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review. | 2020 | Details |
| A08549 | 32064966 | Expert Rev Gastroenterol Hepatol | Sarcopenia in nonalcoholic fatty liver disease: new challenges for clinical practice. | 2020 | Details |
| A08552 | 32063885 | Front Endocrinol (Lausanne) | Bone Turnover Markers and Probable Advanced Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Men and Postmenopausal Women With Type 2 Diabetes. | 2020 | Details |
| A08553 | 32063504 | Ann Hepatol | Prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus. Time for screening? | 2020 | Details |
| A08557 | 32061907 | Metabolism | Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. | 2020 | Details |
| A08561 | 32061595 | Gastroenterology | Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. | 2020 | Details |
| A08564 | 32060386 | Sci Rep | Multiparametric MR Index for the Diagnosis of Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease. | 2020 | Details |
| A08572 | 32055946 | Eur Radiol | Assessment of liver fibrosis severity using computed tomography-based liver and spleen volumetric indices in patients with chronic liver disease. | 2020 | Details |
| A08574 | 32054943 | Sci Rep | Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease. | 2020 | Details |
| A08582 | 32051820 | Can J Gastroenterol Hepatol | Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach. | 2020 | Details |
| A08587 | 32049637 | BMJ Open Diabetes Res Care | Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. | 2020 | Details |
| A08589 | 32048317 | J Gastroenterol Hepatol | Nonalcoholic fatty liver disease burden: Australia, 2019-2030. | 2020 | Details |
| A08591 | 32047809 | Biomed Res Int | Recombinant Lactococcus lactis Expressing Ling Zhi 8 Protein Ameliorates Nonalcoholic Fatty Liver and Early Atherogenesis in Cholesterol-Fed Rabbits. | 2020 | Details |
| A08592 | 32046285 | Biomedicines | NAFLD Preclinical Models: More than a Handful, Less of a Concern? | 2020 | Details |
| A08593 | 32046101 | Int J Mol Sci | Adaptation of Mitochondrial Substrate Flux in a Mouse Model of Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A08595 | 32045667 | Pharmacol Res | Human antigen R: A potential therapeutic target for liver diseases. | 2020 | Details |
| A08598 | 32044884 | Appl Immunohistochem Mol Morphol | Novel Interplay Between Sonic Hedgehog and Transforming Growth Factor-β1 in Human Nonalcoholic Steatohepatitis. | 2020 | Details |
| A08599 | 32044821 | Eur J Gastroenterol Hepatol | Non-alcoholic fatty liver disease in inflammatory bowel disease patients. | 2020 | Details |
| A08600 | 32044522 | Biomaterials | Efficacy of primary liver organoid culture from different stages of non-alcoholic steatohepatitis (NASH) mouse model. | 2020 | Details |
| A08602 | 32044315 | Gastroenterology | Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. | 2020 | Details |
| A08605 | 32043752 | Liver Int | Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH. | 2020 | Details |
| A08609 | 32043602 | Aliment Pharmacol Ther | Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. | 2020 | Details |
| A08611 | 32042452 | Curr Health Sci J | Before and After Treatment Quantitative Assessment of Hepatic Steatosis in a Romanian Population Using Magnetic Resonance Liver Spectroscopy. | 2019 | Details |
| A08616 | 32040895 | Klin Lab Diagn | [The Diagnostic Importance of Circulating MicroRNA for Non-Alcoholic Fatty Liver Disease (review of literature).] | 2019 | Details |
| A08617 | 32040876 | Lipids | Gut microbial fatty acid metabolites (KetoA and KetoC) affect the progression of nonalcoholic steatohepatitis and reverse cholesterol transport metabolism in mouse model. | 2020 | Details |
| A08619 | 32039405 | JHEP Rep | A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage. | 2020 | Details |
| A08623 | 32039393 | JHEP Rep | Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice. | 2019 | Details |
| A08625 | 32039382 | JHEP Rep | From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. | 2019 | Details |
| A08627 | 32039370 | JHEP Rep | Quantitative digital pathology reveals association of cell-specific PNPLA3 transcription with NAFLD disease activity. | 2019 | Details |
| A08628 | 32039369 | JHEP Rep | Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. | 2019 | Details |
| A08632 | 32039349 | JHEP Rep | Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load. | 2019 | Details |
| A08633 | 32038642 | Front Immunol | The Interplay Between Tissue Niche and Macrophage Cellular Metabolism in Obesity. | 2020 | Details |
| A08635 | 32037512 | Br J Pharmacol | P7C3-A20 alleviates fatty liver by shaping gut microbiota and inducing FGF21/FGF1, via the AMP-activated protein kinase/CREB regulated transcription coactivator 2 pathway. | 2020 | Details |
| A08638 | 32036510 | Dig Dis Sci | Omega-3 Fatty Acids and Gut Microbiota: A Reciprocal Interaction in Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A08646 | 32033764 | Gastroenterol Clin North Am | How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis. | 2019 | Details |
| A08648 | 32033762 | Gastroenterol Clin North Am | Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant. | 2020 | Details |
| A08649 | 32033761 | Gastroenterol Clin North Am | Similarities and Differences Between Nonalcoholic Steatohepatitis and Other Causes of Cirrhosis. | 2019 | Details |
| A08652 | 32033758 | Gastroenterol Clin North Am | Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis. | 2020 | Details |
| A08656 | 32031683 | Hepatology | Hepatic Deficiency of Augmenter of Liver Regeneration Predisposes to Nonalcoholic Steatohepatitis and Fibrosis. | 2020 | Details |
| A08658 | 32029710 | Cell Death Dis | Hepatocyte caveolin-1 modulates metabolic gene profiles and functions in non-alcoholic fatty liver disease. | 2020 | Details |
| A08659 | 32029622 | Science | An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis. | 2020 | Details |
| A08667 | 32027911 | Gastroenterology | Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. | 2020 | Details |
| A08669 | 32027858 | Lancet Gastroenterol Hepatol | FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. | 2020 | Details |
| A08676 | 32025168 | J Clin Exp Hepatol | NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet? | 2019 | Details |
| A08682 | 32023709 | Zhonghua Gan Zang Bing Za Zhi | [Value of detection of extracellular vesicles in the diagnosis of nonalcoholic fatty liver disease]. | 2020 | Details |